GC
BIB icon

Garde Capital’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Garde Capital’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-236
Closed -$10.8K – 312
2025
Q2 		$10.8K Hold
236
– – ﹤0.01% 500
2025
Q1 		$11.4K Buy
+236
New +$12.7K ﹤0.01% 479

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Garde Capital's BIB Position: Q3 2025 in Review

Garde Capital sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2025, closing a stake of 236 shares — an estimated $10.8K sold.

Garde Capital first reported a position in BIB in Q1 2025 and held it in 2 quarters. The position peaked at $11.4K in Q1 2025. 19 funds tracked by Wall St. Rank hold BIB as of Q3 2025.

  • Garde Capital reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2025 after selling out during the quarter.
  • Garde Capital sold 236 ProShares Ultra NASDAQ Biotechnology shares in Q3 2025, an estimated $10.8K.
  • Garde Capital first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2025 and held it in 2 quarters.
  • Garde Capital's ProShares Ultra NASDAQ Biotechnology position peaked at $11.4K in Q1 2025.
  • 19 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2025.

Based on Garde Capital's 13F filing for Q3 2025, filed 16 Dec 2025.